Page 66 - 南京医科大学自然版
P. 66
第44卷第4期
·504 · 南 京 医 科 大 学 学 报 2024年4月
异常表达 IL⁃10,白血病细胞产生的 IL⁃10 通过自分 [6] PARK Y,LIM J,KIM S,et al. The prognostic impact of
泌机制支持其白血病细胞的生存 [15] 。IFN⁃γ能够阻 lymphocyte subsets in newly diagnosed acute myeloid leu⁃
碍体外白血病细胞增殖,IFN⁃γ与IL⁃1β等因子具有 kemia[J]. Blood Res,2018,53(3):198
协同抗白血病作用;TNF⁃α可能是白血病细胞存活和 [7] TSIMBERIDOU A M,ESTEY E,WEN S J,et al. The prog⁃
nostic significance of cytokine levels in newly diagnosed
增殖的重要因子,是不良预后因素 。本研究发现伴
[16]
acute myeloid leukemia and high ⁃ risk myelodysplastic
FLT3突变的AML患者治疗前外周血IL⁃6、IL⁃10表达
syndromes[J]. Cancer,2008,113(7):1605-1613
水平较正常对照组升高,而IL⁃2、TNF、IFN⁃γ表达水
[8] LUCIANO M,KRENN P W,HOREJS⁃HOECK J. The cy⁃
平较正常对照组降低,部分细胞因子的表达异常提
tokine network in acute myeloid leukemia[J]. Front Im⁃
示患者预后不良,可能与患者的血细胞计数及FLT3 munol,2022,13:1000996
突变及突变亚型有关,这对进一步探索细胞因子如 [9] RUTERBUSCH M,PRUNER K B,SHEHATA L,et al. In
何影响患者预后有一定的指导意义。 vivo CD4 T cell differentiation and function:revisiting
+
按不同的血细胞计数分组,其淋巴细胞亚群及 the Th1/Th2 paradigm[J]. Annu Rev Immunol,2020,38:
细胞因子,表达水平具有一定的差异性。不同的 705-725
血细胞计数对 AML 患者的预后可能有着一定的影 [10]KNAUS H A,BERGLUND S,HACKL H,et al. Signatures
+
of CD8 T cell dysfunction in AML patients and their re⁃
响 [17] ,而淋巴细胞亚群和细胞因子同样对患者的预
versibility with response to chemotherapy[J]. JCI Insight,
后有着重要影响,提示AML患者预后受综合因素的
2018,3(21):e120974
影响。FLT3基因有着多种突变类型,不同的基因突
[11]DOLINA J S,VAN BRAECKEL⁃BUDIMIR N,THOMAS
变对患者的预后有着不同的影响 [18] 。本研究根据
+
G D,et al. CD8 T cell exhaustion in cancer[J]. Front Im⁃
患者FLT3突变类型进一步分组,亦发现不同的分组 munol,2021,12:715234
间,淋巴细胞亚群和细胞因子表达水平具有差异 [12]WANG H,FU B B,GALE R P,et al. NK⁃/T⁃cell lympho⁃
性,是否不同类型的突变对患者的免疫微环境有 mas[J]. Leukemia,2021,35(9):2460-2468
着影响,进而影响了患者的预后仍需进一步验 [13]ZHANG Y J,GUO H Z,ZHANG Z L,et al. IL⁃6 promotes
证。本研究样本量较小,现有资料不具备预后预 chemoresistance via upregulating CD36 mediated fatty
测作用,后续将继续纳入新的数据,进一步探索不 acids uptake in acute myeloid leukemia[J]. Exp Cell
Res,2022,415(1):113112
同血细胞计数及 FLT3 亚型分组下,不同淋巴细胞
[14]CHEN T T,ZHANG G Z,KONG L Z,et al. Leukemia⁃de⁃
亚群及细胞因子表达水平对患者生存期及缓解率
rived exosomes induced IL⁃8 production in bone marrow
等的影响。
stromal cells to protect the leukemia cells against chemo⁃
[参考文献] therapy[J]. Life Sci,2019,221:187-195
[15]BINDER S,LUCIANO M,HOREJS⁃HOECK J. The cyto⁃
[1] VAGO L,GOJO I. Immune escape and immunotherapy of
kine network in acute myeloid leukemia(AML):a focus
acute myeloid leukemia[J]. J Clin Investig,2020,130
on pro ⁃ and anti ⁃ inflammatory mediators[J]. Cytokine
(4):1552-1564
Growth Factor Rev,2018,43:8-15
[2] ZHAO J C,AGARWAL S,AHMAD H,et al. A review of
[16]NIU L T,WANG Y Q,WONG C C L,et al. Targeting IFN⁃
FLT3 inhibitors in acute myeloid leukemia[J]. Blood
γ⁃inducible lysosomal thiol reductase overcomes chemore⁃
Rev,2022,52:100905
sistance in AML through regulating the ROS⁃mediated mi⁃
[3] KIYOI H,KAWASHIMA N,ISHIKAWA Y. FLT3 muta⁃
tochondrial damage[J]. Transl Oncol,2021,14(9):
tions in acute myeloid leukemia:therapeutic paradigm be⁃
101159
yond inhibitor development[J]. Cancer Sci,2020,111
[17]CHEN Y,XIE Y Y,FANG Y,et al. Correlation of blood
(2):312-322
cell counts with mutant subtypes and impact prognosis in
[4] GUAN W,ZHOU L,LI Y,et al. Profiling of somatic muta⁃
acute myeloid leukemia patients with FLT3 mutations[J].
tions and fusion genes in acute myeloid leukemia patients
Hematology,2023,28(1):2172296
with FLT3⁃ITD or FLT3⁃TKD mutation at diagnosis
[18]NASEEM S,BINOTA J,VARMA N,et al. NPM1 and FLT3⁃
reveals distinct evolutionary patterns[J]. Exp Hematol
Oncol,2021,10(1):27 ITD/TKD gene mutations in acute myeloid leukemia[J].
[5] DANGE P,TYAGI S,JUNEJA R,et al. Study of bone Int J Hematol Oncol Stem Cell Res,2021,15(1):15-26
marrow lymphocyte subset in acute myeloid leukemia[J]. [收稿日期] 2023-06-04
(本文编辑:戴王娟)
J Lab Physicians,2022,14(2):151-156